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Abstract
Background: Elderly patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have poor prognosis.
Autologous CD19 chimeric antigen receptor-modified T (CAR-T) cells have potentials to cure patients with B cell
ALL; however, safety and efficacy of allogeneic CD19 CAR-T cells are still undetermined.
Case presentation: We treated a 71-year-old female with relapsed and refractory ALL who received co-infusion of
haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC) following
induction chemotherapy. Undetectable minimal residual disease by flow cytometry was achieved, and full donor
cell engraftment was established. The transient release of cytokines and mild fever were detected. Significantly
elevated serum lactate dehydrogenase, alanine transaminase, bilirubin and glutamic-oxalacetic transaminase were
observed from days 14 to 18, all of which were reversible after immunosuppressive therapy.
Conclusions: Our preliminary results suggest that co-infusion of haplo-identical donor-derived CAR-T cells and
mobilized PBSCs may induce full donor engraftment in relapsed and refractory ALL including elderly patients, but
complications related to donor cell infusions should still be cautioned.
Trial registration: Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL. NCT02799550
Keywords: Allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells, Haplo-identical mobilized peripheral blood
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Background
The outcome of relapsed and/or refractory acute lympho-
blastic leukemia (ALL) in elderly patients still remains
poor. CD19-directed chimeric antigen receptor-modified
T (CAR-T) cells exhibit powerful capability to eliminate
leukemia cells and showed a high CR rate and curable
effect in patients with relapsed ALL [1, 2]. However,
patients who have extremely high leukemia burden may
meet with difficulty in collecting sufficient T cells, and
prolonged B cell aplasia is another problem. Although
allogeneic CAR-T cells have potentials to overcome some
limitations of autologous CAR-T cells, the efficiency and
graft-versus-host disease (GVHD) in the non-transplant
background are still undetermined [3].
We previously reported improved survival of leukemia
patients who were treated by infusion of haplo-identical
granulocyte colony-stimulating factor (G-CSF)-mobilized
peripheral blood stem cells (G-PBSCs) following chemo-
therapy (microtransplantation), and limited GVHD was
present [4, 5]. Emerging evidence has shown that donor-
derived CAR-T cells functioned well after allogeneic stem
cell transplantation (allo-SCT), which implied that donor
G-PBSCs may support donor-derived CAR-T cell survival
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in the recipient [6]. However, the safety and efficacy of
allogeneic CAR-T cells in combination with G-PBSCs for
leukemia patients are unclear. To evaluate the feasibility
of this strategy, we initiated a phase I clinical trial, and
here, we report one elderly patient with relapsed and
refractory B cell ALL using the co-infusion of haplo-
identical donor-derived CD19-directed CAR-T cells and
G-PBSCs and achieved full donor cell engraftment.
Case presentation
A 71-year-old female was admitted to the hospital because
of pancytopenia. Complete blood count with manual dif-
ferentiation showed 68% blasts, and bone marrow smear
showed 68.5% blasts. Flow cytometry analysis revealed
41.7% cCD79a+, 97.2% CD19+, 69.5% CD20+, 54.5%
CD10+, 97.3% CD38+, and 91.4% HLA-DR. She had nor-
mal female karyotype, and no fusion genes were detected.
The primary diagnosis was ALL. She was treated with
vindesine, mitoxantrone, cyclophosphamide, and dexa-
methasone as induction and achieved complete remission.
A consolidation was given with the same regimen as
induction. The patient suffered from fever and bone pain
2 months after the last chemotherapy, and repeated bone
marrow smear showed 73% lymphoblasts. Two cycles of
re-induction chemotherapy were initiated consisting of
vindesine, fludarabine, cyclophosphamide, and prednis-
one; however, she failed to achieve the second remission.
The bone marrow examination was repeated and
showed 98% lymphoblasts with the same immunophe-
notype as primary diagnosis. Her karyotype shifted to
42-46, X, -X[11], add(2)(P25)[7], ?del(6)(q22)[8], -7[7],
?add(8)(q24)[3], +mar1-2[11][cp15] / 46, XX[7]. She
was diagnosed with relapsed and refractory B cell ALL
and was the first patient enrolled in this phase I clinical
trial (NCT02799550). A re-induction chemotherapy
was administered (vindesine, idarubicin, pegaspargase,
and dexamethasone) which was followed by co-infusion
of haplo-identical donor-derived CD19-directed CAR-T
cells and G-PBSCs. Both CAR-T cells and G-PBSCs
were from her son, who had 6/10 human leukocyte
antigen (HLA) loci matched with the patient. Peripheral
blood for CAR-T cell preparation was collected ahead
of mobilization, and the materials and methods to
produce, detect, and quantify CD19-directed CAR-T
cells were reported previously [7] and detailed in
Additional file 1. Mobilization and apheresis of donor
peripheral mononuclear cells were described previously
[5]. CAR-T cells were infused from the second to fifth
day with escalating doses, and G-PBSCs were infused at
the fourth day post chemotherapy (Fig. 1a).
Response to treatment
Leukemic cells in the bone marrow were undetectable
15 days after the first CAR-T cell infusion (Fig. 2a), and
minimal residual disease was also negative by flow
cytometry in the bone marrow. Although the white
blood cell count remained less than 0.5 × 109/L 26 days
after the first CAR-T cell infusion, the proportion of
CD3+CD19− cells in nucleated cells in peripheral blood
elevated to 90% and CD3−CD19+ cells decreased
dramatically to 0.1% 21 days after the first CAR-T cell
infusion (Fig. 2b, c).
Toxicity
The patient developed a fever (38.3 °C) with chill 1.5 h after
the infusion of CAR-T cells on day 0, and the temperature
returned to normal within 3 h without the administration
of steroids and antibiotics. Intermittent fever occurred ac-
companied by a sharp elevation of C-reaction protein (peak
value 336 mg/L on day 3) during the following days after
the first infusion of CAR-T cells, and sepsis of Escherichia
coli was confirmed through blood culture. Antibiotics were
administrated and the fever was well controlled. No imme-
diate infusion-related toxicity was noted during the infusion
of CAR-T cells on days 1, 2, or 3.
Significantly elevated serum lactate dehydrogenase
(LDH), alanine transaminase (ALT), glutamic-oxalacetic
transaminase (GOT), and bilirubin were present from day
14, and the peak was observed and associated with skin
rash in the neck area from days 15 to 18 (Fig. 2d). It was
suspected as mild GVHD (no biopsy confirmation) al-
though no severe diarrhea occurred. Methylprednisolone
and tacrolimus were administered from days 14 and 15,
respectively, and anti-CD25 antibody was given on days
14 and 16. As our previous study in haplo-identical non-
myeloablative stem cell transplantation showed that intra-
bone marrow injection of mesenchymal stem cells (MSCs)
could prevent severe acute GVHD [8], MSCs from an un-
related donor with a number of 5 × 105/kg per day were
injected directly to the bone marrow cavity on days 18, 21,
and 25 (Fig. 1b). The materials and methods to produce
MSCs were detailed in Additional file 2. The ALT, GOT,
LDH, and bilirubin significantly decreased on days 18 and
19, respectively; however, bilirubin had a trend to elevate
again from day 21 (Fig. 2d).
Engraftment
We monitored donor cell engraftment in the periph-
eral blood and bone marrow by standard cytogenetic
analysis and semi-quantitative polymerase chain reac-
tion (PCR)-based analysis. Donor cells accounted for
14% of whole cells on day 8 after the first CAR-T cell
infusion, which increased gradually to 100% on day
21 (Fig. 2a).
Expansion of donor-derived CAR-T cells in vivo
The highest level of the allogeneic CAR gene in the
peripheral blood was reached on day 7 after the first
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infusion of CAR-T cells with a copy number of 360 per
ug of DNA which was within twofold of the baseline
and associated with decrease of the percentage of CD3
−CD19+ cells (Fig. 2b, e). The level of CAR dropped to
279 copies on day 17.
Cytokine changes
Serum levels of IL-6, IL-8, IL-10, and TNF-α elevated
markedly on day 3 after 3-day infusions of CAR-T
cells (Fig. 2f ). No signs of severe cytokine-release syn-
drome (CRS) or tumor lysis syndrome (TLS) were
observed.
Survival
The patient exhibited slight recovery of neutrophil count
on day 26 after the first infusion of CAR-T cells; however,
she refused any further treatment and was discharged on
day 26 because of financial problems. She died from
severe infection on day 31.
Discussion and Conclusion
In this study, a 71-year-old relapsed and refractory ALL
patient received co-infusion of haplo-identical donor-
derived CD19-directed CAR-T cells and G-PBSCs and
achieved full donor cell engraftment with mild toxicity.
a
b
Fig. 1 Protocol of haplo-identical CAR-T cell and G-PBSC infusions following chemotherapy and treatment for “GVHD-like” reaction. a Protocol of CAR-T
and G-PBSC infusion in combination with chemotherapy. Chemotherapy included vindesine, idarubicin, pegaspargase, and dexamethasone. CAR-T cells
were infused at a total dose of 0.32 × 108/kg CD3+ cells (0.15 × 108/kg CAR-T cells), and the numbers of mononuclear, CD34+ and CD3+
cells infused in the G-PBSCs were 1.82 × 108/kg, 1.93 × 106/kg, and 0.46 × 108/kg, respectively. b Flow chart of treatment after developing
“GVHD-like” reaction. Methylprednisolone at a dose of 3 mg/kg per day was administered intravenously right after the finding of liver dysfunction from
day 14, and tacrolimus at a dose of 0.03 mg/kg per day was started intravenously on day 15. Anti-CD25 antibody at a dose of 25 mg per day was given
on days 14 and 16. Mesenchymal stem cells with a number of 5 × 105/kg per day were injected to the bone marrow cavity on days 18, 21, and 25
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Fig. 2 (See legend on next page.)
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It is speculated that allogeneic CAR-T cells may have
potential benefit of reserving alloreactive-attacking cap-
ability to leukemic cells and help overcome limitation of
autologous CAR-modified T cells [9]. However, it is
unclear whether allogeneic CAR-T cells may persist and
proliferate in vivo. In this patient, we persistently
detected donor CAR-T cells within twofold of the base-
line in host peripheral blood. These results suggested
that allogeneic CAR-T cells can survive in vivo although
their proliferative efficiency is much lower than that
previously reported in which autologous CAR-T cell
number amplifies thousands of times in vivo [1]. The
anti-CD25 monoclonal antibody has been reported to
eliminate donor-specific alloreactive T cells via blockade
of the IL-2 binding site and then to prevent and treat
acute GVHD [10, 11, 12]. However, no studies have in-
vestigated its influence to CAR-T cells. We treated this
patient with anti-CD25 antibody on days 14 and 16,
which was in accordance with the drop of the allogeneic
CAR gene (Figs. 1b and 2e), implying the potential
adverse impact of anti-CD25 antibody on CAR-T cell
persistence and activation. It is also uncertain whether
sustained pancytopenia in this patient suppressed prolif-
eration of CD19-positive cells and consequently attenu-
ated amplification activity of CAR-T cells. In fact, the
persistence of CAR-T cells leads to prolonged B cell
aplasia [1]. Allogeneic CAR-T cells may also cause
donor/recipient-derived B cell clearance (Fig. 2b). There-
fore, transient or low level expression of allogeneic
CAR-T cells may facilitate donor/recipient-derived B cell
reconstitution and simultaneously reserve anti-leukemic
effect.
Another major concern is the safety of allogeneic
CAR-T cells, particularly for severe GVHD. In this study,
the patient developed obvious liver dysfunction and skin
rash associated with donor cell engraftment, but no
severe hypotension and polypnea were observed al-
though mild elevated levels of cytokines including IL-6,
IL-8, IL-10, and TNF-α were found. Therefore, we prefer
to name it as a mild “GVHD-like” reaction instead of
CRS in this patient. This reaction may correlate with
low-intensity chemotherapy conditioning and CAR-T
cell-mediated specific anti-leukemic action prior to the
G-PBSC infusion, which suppressed patient’s normal im-
mune function and consequently induced development
of GVHD under the absence of GVHD prevention. This
patient established full donor chimerism following a
simple combined chemotherapy and infusions of allo-
geneic G-PBSCs and CD19-directed CAR-T cells, which
may in part attribute to low proportion of recipient CD3
+CD19− T cells prior to cell infusions (Fig. 2b). Although
a preclinical study reported CAR-T cells as a component
of conditioning regimen of standard transplantation
[13], whether allogeneic CAR-T cells improve engraft-
ment is still undetermined. Further investigations will
focus on a clinical study to evaluate the feasibility of this
strategy in future.
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Fig. 2 Clinical responses to infusions of haplo-identical CAR-T cells and G-PBSCs in the patient with ALL. a Leukemic cells in the bone marrow
decreased and were finally undetected 15 days after the first CAR-T cell infusion. Meanwhile, the percentage of donor cells elevated to 100%
21 days after the first CAR-T cell infusion. b White blood cell count recovered slowly after the first CAR-T cell infusion, and the proportion of CD3
+CD19−cells in nucleated cells in peripheral blood elevated to 90% and CD3−CD19+ cells decreased dramatically to 0.1% 21 days after the first
CAR-T cell infusion. c Changes in the platelet count and hemoglobin level. d Elevated serum LDH, ALT, and GOT were detected on day 14. Levels
of ALT and GOT achieved the peak on day 15. The level of LDH reached the peak on day 17. Elevations of TB and DB were also present following
rises of LDH, ALT, and GOT and reached the peak on day 18. e Levels of the allogeneic CAR gene were monitored. The highest level in the
peripheral blood was reached on day 7 with a copy number within twofold of the baseline. f Serum levels of cytokines were measured at the
indicated time points before or after CAR-T cell and G-PBSC infusions. Levels of IL-6, IL-8, IL-10, and TNF-α elevated markedly on day 3 and then
dropped quickly
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